Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/ Pibrentasvir (Mayret) in Chronic Hepatitis C Patients (SMART-C)
Data has shown that direct-acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor respectively, provides key features for HCV treatment simplification.
Eligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to the standard or simplified monitoring arm and will receive treatment for 8 weeks.
One post-treatment visit will be conducted 12 weeks after the final dose of study medication to evaluate the proportion of patients with undetectable HCV RNA at this time point (SVR12).
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1 (a blood test)
Cryoglobulinemia vasculitis (inflammation of blood vessels) is a disorder caused by the hepatitis C virus. The symptoms and health problems of cryoglobulinemia can be mild to moderate to severe and for some people cryoglobulinemia can be life-threatening. Treating cryoglobulinemia with direct-acting antiviral medications has been shown to improve the symptoms and complications of cryoglobulinemia and for some people successful HCV treatment can cure it.
This objective of this clinical trial is to treat and cure hepatitis C and measure the effect of curing hepatitis C on HCV-related cryoglobulinemia vasculitis.
France: Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
To view the entire clinical trial information, click here
This is an observation study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Viekira Pak (with and without ribavirin) in genotype 1 and 4 patients. This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepatitis C genotype 1 (cure rates = 95 to 100%) and genotype 4 (cure rates = 91 to 100%).
France: The Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)